Evogene Q1 Revenue Falls 87% to $0.3M, Net Loss Widens to $5.9M
EVGN•Evogene Ltd’s Q1 2026 revenue plunged to $0.3 million from $2.3 million year-over-year, driving a net loss expansion to roughly $5.9 million. The company has scaled back subsidiaries, terminated its Bayer collaboration over target-protein issues, and is advancing new Pharma and AgPlenus partnerships including a fungicide program.
1. Q1 Financial Results
Evogene reported revenue of $0.3 million for the first quarter of 2026, down from $2.3 million in Q1 2025, and recorded a net loss of approximately $5.9 million, reflecting increased operating expenses and decreased financing income.
2. Operational Restructuring
The company has discontinued or significantly scaled back activities in subsidiaries such as Lavie Bio and Biomica, reducing its operational scope to focus resources on core technology platforms and high-potential collaborations.
3. Partnership Updates
Evogene terminated its ag-chemical collaboration with Bayer due to biology issues with the target protein but is advancing its AgPlenus internal fungicide project for Septoria and has launched new Pharma division collaborations targeting hyperinflammatory, demyelinating and chemotherapy-resistance indications.
4. Strategic Outlook
Management is pursuing further strategic collaborations, including a second ChemPass AI partnership with Google, and expects future equity investments and transactions to hinge on milestones achieved in its agricultural and pharmaceutical programs.
